INDIANAPOLIS, March 21, 2016 -- PTS Diagnostics, the U.S.-based manufacturer of point-of-care biometric testing devices, including the CardioChek® family of analyzers, A1CNow® systems, and PTS Detect™ cotinine systems, announced today that they have signed a national sales and distribution agreement with Anda, an Allergan company. Anda is a national medical distribution company that sells over-the-counter pharmaceutical products to retail independent and chain pharmacies, nursing homes, mail-order pharmacies, hospitals, clinics and physician offices.
“Anda is well positioned with many of the key market segments that PTS Diagnostics’ portfolio of products serves,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “We are quite pleased Anda will become our newest distributor in the United States. Given our medical devices’ ability to measure point-of-care results for lipids (cholesterol), A1C, and cotinine as well as the ability to offer many more laboratory tests with a simple fingerstick, we anticipate significant further growth within the pharmacy, clinic and physician office settings.”
Founded in 1992, Anda is the fourth largest supplier of generic pharmaceuticals in the U.S., and is a premier distributor for new-to-market product launches to retail chains. With over 60,000 locations to sell to and 220 sales representatives making 18,000 telephone calls a day, Anda stocks more than 10,000 line items.
“Point-of-care testing is rapidly growing among pharmacies, hospitals, clinics and physician offices,” said Anthony Mihelich, Anda’s Vice President of Purchasing. “PTS Diagnostics CardioChek lipid analyzers, A1CNow+ systems and PTS Detect cotinine systems are prime for expansion within these markets. We stock the latest technologically advanced products that are in high demand with our customers. The PTS Diagnostics portfolio of products fills this market need nicely.”
PTS Diagnostics also offers critical information management functionality with digital capture and transfer of biometric screening information with its PTS Connect solutions. This suite of digital products make connectivity flexible and information management simple. In addition, the PTS Connect wellness solution provides an online account for wellness program participants to view biometric information and monitor ongoing health improvement.
About PTS Diagnostics
PTS Diagnostics is an innovative, global, point-of-care diagnostics solutions provider that partners with patients and healthcare professionals to provide the right information at the right time to make the right decision. The company’s name represents the three pillars upon which it has built its long-term success: People, Technology and Service. Headquartered in Indianapolis, Indiana, PTS Diagnostics designs, manufactures, distributes and markets products for distribution in more than 135 countries around the world. For more information, visit www.ptsdiagnostics.com or contact Tom Wiser at 317-870-5610 or [email protected].
Tom Wiser 317-517-2216


Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions
Want to cut your energy bills? Here’s how five experts are doing it
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank
John Ternus Signals Apple’s Future with Product-First AI Strategy
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 



